Knight Therapeutics gains rights to Sumitomo Pharma products in Canada

9 June 2025

Canada-based Knight Therapeutics (TSX: GUD) and the US subsidiary of Japan’s Sumitomo Pharma (TYO: 4506) have entered into exclusive license and supply agreements to commercialize certain products.

These are Myfembree (relugolix/estradiol/norethindrone acetate), Orogvyx (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight will acquire certain mature products. For the year ended March 2025, the Products generated C$11.2 million (~$8 million) in revenue.

Knight will have the exclusive rights to distribute, promote, market and sell the products in Canada, and said it will begin commercial activities following a transition period from Sumitomo Pharma Canada.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK